Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565494 | 1.00 | HRH4 (0.41) | HRH4TBK1IKBKEEHMT2EHMT1 | |
| SCHEMBL17750626 | 0.95 | ACHE (0.39) | TBK1IKBKECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17750240 | 0.88 | TBK1 (0.38) | HRH4TBK1IKBKEEHMT2EHMT1 | |
| SCHEMBL21279021 | 0.87 | PDE10A (0.38) | TBK1IKBKECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16091613 | 0.87 | PDE10A (0.38) | TBK1IKBKECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17750293 | 0.87 | TBK1 (0.43) | HRH4TBK1IKBKEEHMT2EHMT1 | |
| SCHEMBL17750530 | 0.86 | SYK (0.39) | TBK1IKBKEGPR6PDE10ASYK | |
| SCHEMBL21179460 | 0.86 | TBK1 (0.39) | HRH4TBK1IKBKEEHMT2EHMT1 | |
| SCHEMBL21187294 | 0.86 | TBK1 (0.39) | HRH4TBK1IKBKEEHMT2EHMT1 | |
| SCHEMBL17750362 | 0.86 | TTK (0.38) | TBK1IKBKEGPR6PDE10ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| US-10973830-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210060028-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-03-04 | — | — | US | disclosed |
| US-20190290654-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2019143675-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
| EP-2970218-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2018-11-28 | — | — | EP | disclosed |
| US-9987284-B2 | Substituted benzooxadiazole DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160340341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-24 | — | — | US | disclosed |
| US-9340557-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | disclosed |
| WO-2014159690-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973830-B2 | Substituted quinoxaline DNA-PK inhibitors | TOP1, TOP2A, TOP2B | HRH4 1106/4885TBK1 623/4885IKBKE 697/4885 |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | DTYMK, POLK, TOP1 | HRH4 1646/4885TBK1 426/4885IKBKE 810/4885 |
| US-20190290654-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | HRH4 2433/4885TBK1 506/4885IKBKE 487/4885 |
| US-20160340341-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | HRH4 2433/4885TBK1 506/4885IKBKE 487/4885 |
| US-20210060028-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | HRH4 2613/4885TBK1 475/4885IKBKE 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.